The U.S. IPO market roared back to life in early February 2026, when seven companies priced new offerings in a single week, one of the busiest stretches for new listings in four years. The wave spanned biotech, industrial equipment and consumer retail names, raising roughly $3 billion combined and signaling renewed risk appetite among investors after a cautious start to the year.
A Packed Week of Pricings
The seven deals covered a wide swath of sectors. Veradermics, a hair-loss biotech, priced 13% above its midpoint range to raise $256 million. Data-center equipment maker Forgent Power Solutions raised $1.5 billion at an $8.2 billion valuation, the week's largest deal. SpyGlass Pharma, focused on chronic eye conditions, raised $150 million, while Once Upon a Farm, an organic baby-food maker, brought in $198 million. Rounding out the week were furniture retailer Bob's Discount Furniture, at $331 million, Belgian biotech AgomAb Therapeutics, at $200 million, and Eikon Therapeutics, led by former Merck executives, which priced its upsized deal at the top of its range for $381 million.
Why Issuers Moved Now
Bankers pointed to a rare confluence of favorable conditions: low volatility, receptive secondary markets and a backlog of issuers waiting for a window to price. The rush also came ahead of a year expected to bring some of the largest listings on record, including SpaceX, Anthropic and OpenAI, all of which advanced IPO plans later in 2026. Smaller and mid-cap issuers had every incentive to price early, before a heavier calendar of mega-deals could crowd out investor attention and available capital later in the year. Renaissance Capital data show 2026 was already on pace to challenge the record set in 2021 for total capital raised through IPOs.
A Mixed Debut Scorecard
Performance on debut was uneven, underscoring that investor selectivity persisted even amid the enthusiasm. Veradermics surged 126% and SpyGlass Pharma jumped 65%, while Forgent Power Solutions added 25% and Once Upon a Farm gained 17%. On the other side, Eikon Therapeutics fell 19%, AgomAb Therapeutics dropped 8% and Bob's Discount Furniture slipped 3%. The wide spread between the best and worst performers highlighted how sector narrative, more than deal size alone, drove first-day demand from investors, with growth-oriented biotech names generally outperforming more mature, defensive businesses like furniture retail.
What It Means for Traders
Busy IPO weeks tend to widen trading ranges across the broader market, as capital rotates toward new issuance and away from existing positions, and as newly listed names add fresh volatility to sector indices. For traders, tracking the calendar of pricings, lockup expirations and follow-on offerings can offer early signals about sector rotation and risk sentiment, particularly when a heavy week like this one clusters around a handful of themes such as AI infrastructure, biotech and consumer discretionary names. Newly listed stocks also tend to carry wider spreads and thinner liquidity in their first weeks of trading, which can amplify both gains and losses.
Daily market analysis by BCM Markets.